JP2018519332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519332A5 JP2018519332A5 JP2017568244A JP2017568244A JP2018519332A5 JP 2018519332 A5 JP2018519332 A5 JP 2018519332A5 JP 2017568244 A JP2017568244 A JP 2017568244A JP 2017568244 A JP2017568244 A JP 2017568244A JP 2018519332 A5 JP2018519332 A5 JP 2018519332A5
- Authority
- JP
- Japan
- Prior art keywords
- benzenesulfonamide
- oxoimidazolidin
- cancer
- alkyl
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 13
- 125000001475 halogen functional group Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 230000004614 tumor growth Effects 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims description 4
- 230000009400 cancer invasion Effects 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 230000001146 hypoxic effect Effects 0.000 claims description 4
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 4
- 230000030833 cell death Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- MTZLLKHAIMENRQ-UHFFFAOYSA-N 4-(3-cyclohexyl-2-oxoimidazolidin-1-yl)benzenesulfonamide Chemical compound C1(CCCCC1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O MTZLLKHAIMENRQ-UHFFFAOYSA-N 0.000 claims description 2
- NBSLWOQVDXHMGP-UHFFFAOYSA-N 4-(3-cyclopentyl-2-oxoimidazolidin-1-yl)benzenesulfonamide Chemical compound C1(CCCC1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O NBSLWOQVDXHMGP-UHFFFAOYSA-N 0.000 claims description 2
- PSRKSQXJSCNCBR-UHFFFAOYSA-N 4-[2-oxo-3-(3,4,5-trimethoxyphenyl)imidazolidin-1-yl]benzenesulfonamide Chemical compound O=C1N(CCN1C1=CC(=C(C(=C1)OC)OC)OC)C1=CC=C(C=C1)S(=O)(=O)N PSRKSQXJSCNCBR-UHFFFAOYSA-N 0.000 claims description 2
- QVLMPIQNPKEIPZ-UHFFFAOYSA-N 4-[2-oxo-3-[4-(trifluoromethyl)phenyl]imidazolidin-1-yl]benzenesulfonamide Chemical compound O=C1N(CCN1C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)S(=O)(=O)N QVLMPIQNPKEIPZ-UHFFFAOYSA-N 0.000 claims description 2
- SGCKOJXZNTVQLM-UHFFFAOYSA-N 4-[3-(2,4-difluorophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound FC1=C(C=CC(=C1)F)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O SGCKOJXZNTVQLM-UHFFFAOYSA-N 0.000 claims description 2
- RPIFFSSUFQKDGF-UHFFFAOYSA-N 4-[3-(2-fluoro-4-methoxyphenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound FC1=C(C=CC(=C1)OC)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O RPIFFSSUFQKDGF-UHFFFAOYSA-N 0.000 claims description 2
- PTXLRHZELJCNJM-UHFFFAOYSA-N 4-[3-(2-fluorophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound FC1=C(C=CC=C1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O PTXLRHZELJCNJM-UHFFFAOYSA-N 0.000 claims description 2
- DSJYWCCBODHQGZ-UHFFFAOYSA-N 4-[3-(3,4-difluorophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound FC=1C=C(C=CC=1F)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O DSJYWCCBODHQGZ-UHFFFAOYSA-N 0.000 claims description 2
- GZTKOIAVJDBSIN-UHFFFAOYSA-N 4-[3-(3,5-difluorophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound FC=1C=C(C=C(C=1)F)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O GZTKOIAVJDBSIN-UHFFFAOYSA-N 0.000 claims description 2
- OXYDLUALOWNOGG-UHFFFAOYSA-N 4-[3-(3,5-dimethylphenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound CC=1C=C(C=C(C=1)C)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O OXYDLUALOWNOGG-UHFFFAOYSA-N 0.000 claims description 2
- HBTDDPWUVQOBEA-UHFFFAOYSA-N 4-[3-(3-chloro-4-fluorophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound ClC=1C=C(C=CC=1F)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O HBTDDPWUVQOBEA-UHFFFAOYSA-N 0.000 claims description 2
- DAFRLQUJYTXPNY-UHFFFAOYSA-N 4-[3-(3-fluorophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound FC=1C=C(C=CC=1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O DAFRLQUJYTXPNY-UHFFFAOYSA-N 0.000 claims description 2
- PVBBZQVAYSHPKC-UHFFFAOYSA-N 4-[3-(4-bromo-2-fluorophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound BrC1=CC(=C(C=C1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O)F PVBBZQVAYSHPKC-UHFFFAOYSA-N 0.000 claims description 2
- LRVMSXMESQWOFK-UHFFFAOYSA-N 4-[3-(4-butoxy-2-fluorophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound C(CCC)OC1=CC(=C(C=C1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O)F LRVMSXMESQWOFK-UHFFFAOYSA-N 0.000 claims description 2
- KYGXSNQBNXNQDC-UHFFFAOYSA-N 4-[3-(4-butoxyphenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound C(CCC)OC1=CC=C(C=C1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O KYGXSNQBNXNQDC-UHFFFAOYSA-N 0.000 claims description 2
- OABKDZAAOUWBTJ-UHFFFAOYSA-N 4-[3-(4-chloro-2-fluorophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound ClC1=CC(=C(C=C1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O)F OABKDZAAOUWBTJ-UHFFFAOYSA-N 0.000 claims description 2
- LNNHZBDLCHSOJV-UHFFFAOYSA-N 4-[3-(4-chloro-3-fluorophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound ClC1=C(C=C(C=C1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O)F LNNHZBDLCHSOJV-UHFFFAOYSA-N 0.000 claims description 2
- MMSVZHYQXBBMJD-UHFFFAOYSA-N 4-[3-(4-cyanophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound C(#N)C1=CC=C(C=C1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O MMSVZHYQXBBMJD-UHFFFAOYSA-N 0.000 claims description 2
- JOZUVLUTFICFFW-UHFFFAOYSA-N 4-[3-(4-fluorophenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound FC1=CC=C(C=C1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O JOZUVLUTFICFFW-UHFFFAOYSA-N 0.000 claims description 2
- CEWIWEYEMRTFDZ-UHFFFAOYSA-N 4-[3-(5-fluoropyridin-2-yl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound FC=1C=CC(=NC=1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O CEWIWEYEMRTFDZ-UHFFFAOYSA-N 0.000 claims description 2
- FKCSIAXXUVYBNN-UHFFFAOYSA-N 4-[3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound C1(CC1)CN1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O FKCSIAXXUVYBNN-UHFFFAOYSA-N 0.000 claims description 2
- VEZUUHQGGGSWBV-UHFFFAOYSA-N 4-[3-[2-chloro-5-(trifluoromethyl)phenyl]-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O VEZUUHQGGGSWBV-UHFFFAOYSA-N 0.000 claims description 2
- YJPALFCHXMNSCU-UHFFFAOYSA-N 4-[3-[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound FC1=C(C=CC(=C1)N1CCN(CC1)C)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O YJPALFCHXMNSCU-UHFFFAOYSA-N 0.000 claims description 2
- MZNKDQKCMWOGKT-UHFFFAOYSA-N 4-[3-[2-fluoro-5-(trifluoromethyl)phenyl]-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound FC1=C(C=C(C=C1)C(F)(F)F)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O MZNKDQKCMWOGKT-UHFFFAOYSA-N 0.000 claims description 2
- CCFZLEIBXREHJV-UHFFFAOYSA-N 4-[3-[4-(2-methoxyethoxy)phenyl]-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound COCCOC1=CC=C(C=C1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O CCFZLEIBXREHJV-UHFFFAOYSA-N 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- GKYZFKNXTDALAC-UHFFFAOYSA-N CC(=O)C1=CC=C(C=C1)N2CCN(C2=O)C3=CC=CC=C3 Chemical compound CC(=O)C1=CC=C(C=C1)N2CCN(C2=O)C3=CC=CC=C3 GKYZFKNXTDALAC-UHFFFAOYSA-N 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 108700012439 CA9 Proteins 0.000 description 5
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000033781 Thyroid carcinoma Diseases 0.000 description 4
- 201000003914 endometrial carcinoma Diseases 0.000 description 4
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 3
- -1 UFT Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- XSCCUSZCDIPOGP-UHFFFAOYSA-N 2-oxo-1,3,2lambda5-diazaphospholidin-2-amine Chemical compound P1(=O)(NCCN1)N XSCCUSZCDIPOGP-UHFFFAOYSA-N 0.000 description 1
- ZNEYPBWDFFLKSW-UHFFFAOYSA-N 4-[3-(4-acetylphenyl)-2-oxoimidazolidin-1-yl]benzenesulfonamide Chemical compound C(C)(=O)C1=CC=C(C=C1)N1C(N(CC1)C1=CC=C(C=C1)S(=O)(=O)N)=O ZNEYPBWDFFLKSW-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 201000007550 esophagus adenocarcinoma Diseases 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187636P | 2015-07-01 | 2015-07-01 | |
| US62/187,636 | 2015-07-01 | ||
| PCT/US2016/040736 WO2017004543A1 (en) | 2015-07-01 | 2016-07-01 | Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519332A JP2018519332A (ja) | 2018-07-19 |
| JP2018519332A5 true JP2018519332A5 (https=) | 2019-07-25 |
| JP6795525B2 JP6795525B2 (ja) | 2020-12-02 |
Family
ID=56411955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568244A Active JP6795525B2 (ja) | 2015-07-01 | 2016-07-01 | 炭酸脱水酵素阻害剤としてのアリールスルホンアミド化合物およびその治療的使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10562859B2 (https=) |
| EP (1) | EP3317255B1 (https=) |
| JP (1) | JP6795525B2 (https=) |
| KR (1) | KR102637759B1 (https=) |
| CN (1) | CN107922345B (https=) |
| AU (1) | AU2016287587B2 (https=) |
| BR (1) | BR112018000065B1 (https=) |
| CA (1) | CA2991168C (https=) |
| IL (1) | IL256527B (https=) |
| MX (1) | MX387267B (https=) |
| WO (1) | WO2017004543A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2931533T3 (es) * | 2017-04-05 | 2022-12-30 | Harvard College | Compuesto macrocíclico y usos del mismo |
| KR20210000564A (ko) | 2019-06-25 | 2021-01-05 | 공주대학교 산학협력단 | 신규 아만타딘 유도체 화합물 및 이의 용도 |
| CN111233786B (zh) * | 2020-02-04 | 2021-11-26 | 中国人民解放军军事科学院军事医学研究院 | 含五元杂环的苯磺酰胺类化合物及其制备方法和用途 |
| JP7514036B2 (ja) * | 2020-06-02 | 2024-07-10 | イェディテペ・ウニヴェルシテシ | 癌の治療のための炭酸脱水酵素ＩＸ阻害剤としての２－（３－（２－メチル－６－（ｐ－トリル）ピリジン－３－イル）ウレイド）ベンゼンスルホンアミドおよびその誘導体 |
| TR202014185A2 (tr) * | 2020-09-08 | 2022-03-21 | Anadolu Ueniversitesi | BAZI YENİ 4-(2-((5-(SÜBSTİTÜEAMİNO)-1,3,4-TİYADİAZOL-2-İL)TİYO)ASETİL)BENZENSÜLFONAMİD TÜREVLERİ ve SÖZ KONUSU TÜREVLERİN SENTEZİ İÇİN BİR YÖNTEM |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003013655A2 (en) * | 2001-08-10 | 2003-02-20 | Pharmacia Corporation | Carbonic anhydrase inhibitors |
| US20130012485A1 (en) * | 2006-12-22 | 2013-01-10 | Baeschlin Daniel Kaspar | Organic compounds |
| WO2012021963A1 (en) | 2010-07-09 | 2012-02-23 | Metasignal Therapeutics Inc. | Novel sulfonamide compounds for inhibition of metastatic tumor growth |
| WO2013023274A1 (en) * | 2011-08-16 | 2013-02-21 | Universite Laval | Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer |
-
2016
- 2016-07-01 KR KR1020187003119A patent/KR102637759B1/ko active Active
- 2016-07-01 US US15/743,601 patent/US10562859B2/en active Active
- 2016-07-01 JP JP2017568244A patent/JP6795525B2/ja active Active
- 2016-07-01 WO PCT/US2016/040736 patent/WO2017004543A1/en not_active Ceased
- 2016-07-01 CA CA2991168A patent/CA2991168C/en active Active
- 2016-07-01 AU AU2016287587A patent/AU2016287587B2/en active Active
- 2016-07-01 MX MX2018000175A patent/MX387267B/es unknown
- 2016-07-01 BR BR112018000065-5A patent/BR112018000065B1/pt active IP Right Grant
- 2016-07-01 CN CN201680046227.7A patent/CN107922345B/zh active Active
- 2016-07-01 EP EP16738988.1A patent/EP3317255B1/en active Active
-
2017
- 2017-12-24 IL IL256527A patent/IL256527B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3011189C (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| JP2018519332A5 (https=) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| BR112017016193B1 (pt) | Derivados de 4h-pirrolo[3,2-c]piridin-4-ona | |
| TW201840549A (zh) | 2-雜芳基-3-氧代-2,3-二氫噠嗪-4-甲醯胺 | |
| JP2008528467A5 (https=) | ||
| JP2017530962A (ja) | Ｂｕｂ１阻害薬としてのベンジル置換インダゾール類 | |
| PT2791136E (pt) | Triazolpiridinas substituídas e respectiva utilização como inibidores de ttk | |
| IL291590B2 (en) | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | |
| AU2015217788A1 (en) | Benzimidazol-2-amines as mIDH1 inhibitors | |
| JP2016517878A5 (https=) | ||
| WO2024079252A1 (en) | Sos1 inhibitors | |
| TW202304467A (zh) | 作為新穎ｓｏｓ１抑制劑之磷衍生物 | |
| JP2017505793A (ja) | ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン | |
| JP2017532360A5 (https=) | ||
| US11660301B2 (en) | Combination of ATR kinase inhibitors with PARP inhibitors | |
| JP2014531436A5 (https=) | ||
| JP2017502967A5 (https=) | ||
| CN106414435A (zh) | 氨基‑取代的异噻唑 | |
| WO2016062677A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| WO2018206547A1 (en) | Combination of bub1 and atr inhibitors | |
| AU2015239548A1 (en) | Amido-substituted azole compounds as inhibitors of TNKS1 and/or TNKS2 | |
| WO2017055313A1 (en) | Amido-substituted azole compounds | |
| WO2017055316A1 (en) | Amido-substituted azole compounds |